Acquisition Opportunity Cyprotex is an Evotec-owned ADME-Tox specialist with established in vitro and in silico capabilities and recent expansion into online ordering through e-store. Target sales to Evotec’s vast pharma client base seeking integrated ADME-Tox services and streamlined procurement.

US Footprint Reassessment Recent closure and relocation of the Massachusetts office suggest potential service demand concentration elsewhere or a shift in US capability. Opportunity to propose a scalable, outsourced ADME-Tox solution that mitigates regional footprint constraints for US customers.

Digital Ordering The launch of the e-store enables faster service access and cross-sell of ADME-Tox offerings. Leverage digital procurement channels to upsell advanced testing panels, transcriptomics, and customized ADME assays to existing customers.

Service Expansion Introduced transcriptomics service and GIANTmicrobes mitochondria concept, signaling readiness to broaden high-value assays. Present integrated packages combining in vitro, in silico, and omics capabilities to win larger project scopes.

Financial Tailwinds Mid-sized revenue range with parent backing from Evotec positions Cyprotex to pursue binding multi-year ADME-Tox programs. Highlight stable backing and capability depth when engaging enterprise pharma prospects seeking reliable CRO partnerships.